RNA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.98M

-33.35%

-1.266

+58.27%

2.38M

+51.18%

-1.279

+42.1%

2.38M

-38.18%

-1.309

+8.17%

Estimates Revision

The market is revising Upward the revenue expectations for Avidity Biosciences, Inc. (RNA) for FY2025, with the revenue forecasts being adjusted by 140.72% over the past three months. During the same period, the stock price has changed by 42.54%.

Revenue Estimates for FY2025

Revise Upward

+140.72%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.05%

In Past 3 Month

Stock Price

Go Up

+42.54%

In Past 3 Month

15 Analyst Rating

Wall Street analysts forecast RNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNA is 71.71 USD with a low forecast of 53.00 USD and a high forecast of 96.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

10 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

53.00

Averages

71.71

High

96.00

Current: 0.000

Low

53.00

Averages

71.71

High

96.00

TD Cowen

Ritu Baral

Buy -> Hold

downgrade

$78 -> $74

2025-10-28

Reason

TD Cowen

Ritu Baral

Price Target

$78 -> $74

2025-10-28

downgrade

Buy -> Hold

Reason

TD Cowen analyst Ritu Baral downgraded Avidity Biosciences (RNA) to Hold from Buy with a price target of $74, down from $78, after the company entered into a merger agreement with Novartis (NVS) for $72 per share.

Chardan

Keay Nakae

Buy -> Neutral

downgrade

$72

2025-10-28

Reason

Chardan

Keay Nakae

Price Target

$72

2025-10-28

downgrade

Buy -> Neutral

Reason

Chardan analyst Keay Nakae downgraded Avidity Biosciences (RNA) to Neutral from Buy with a $72 price target after Novartis (NVS) announced an agreement to acquire Avidity for $72 per share in cash. The acquisition is expected to close in the first half of 2026, the analyst tells investors in a research note.

Citi

Geoff Meacham

Buy -> Neutral

downgrade

$72

2025-10-28

Reason

Citi

Geoff Meacham

Price Target

$72

2025-10-28

downgrade

Buy -> Neutral

Reason

Citi analyst Geoff Meacham downgraded Avidity Biosciences (RNA) to Neutral from Buy with an unchanged price target of $72 after the company entered into a merger agreement with Novartis (NVS) for $72 per share. Citi believes a competitive bid is unlikely.

BofA

downgrade

$72

2025-10-27

Reason

BofA

Price Target

$72

2025-10-27

downgrade

Reason

BofA moved to No Rating on Avidity Biosciences (RNA) after the company announced that it has entered into an agreement to be acquired by Novartis (NVS) for about $12B, or $72 per share. Given the deal, the stock is no longer trading on fundamentals, the analyst tells investors.

Citi

Geoff Meacham

Buy -> Neutral

downgrade

$72

2025-10-27

Reason

Citi

Geoff Meacham

Price Target

$72

2025-10-27

downgrade

Buy -> Neutral

Reason

Citi analyst Geoff Meacham downgraded Avidity Biosciences (RNA) to Neutral from Buy with an unchanged price target of $72 after the announcement of the proposed acquisition by Novartis (NVS).

Leerink

Outperform -> Market Perform

downgrade

$72

2025-10-27

Reason

Leerink

Price Target

$72

2025-10-27

downgrade

Outperform -> Market Perform

Reason

Leerink downgraded Avidity Biosciences (RNA) to Market Perform from Outperform with a $72 price target after Novartis (NVS) announced an agreement to acquire Avidity for $72 per share in cash.

Valuation Metrics

The current forward P/E ratio for Avidity Biosciences Inc (RNA.O) is -13.80, compared to its 5-year average forward P/E of -7.33. For a more detailed relative valuation and DCF analysis to assess Avidity Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.33

Current PE

-13.80

Overvalued PE

-3.78

Undervalued PE

-10.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.54

Current EV/EBITDA

-12.22

Overvalued EV/EBITDA

-1.19

Undervalued EV/EBITDA

-7.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

240.04

Current PS

958.74

Overvalued PS

477.01

Undervalued PS

3.07

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

RNA News & Events

Events Timeline

No data

News

7.5

2025-12-31Benzinga

Biotech Stocks Surge at Year-End 2025, ETFs Gain 35.84%

3.0

2025-12-16Benzinga

Two Health Care Stocks That Could Cause You Concern This December

4.5

2025-12-11NASDAQ.COM

ETF Outflow Warning: XBI, EXAS, RVMD, RNA

People Also Watch

Frequently Asked Questions

What is Avidity Biosciences Inc (RNA) stock price today?

The current price of RNA is 72.37 USD — it has increased 0 % in the last trading day.

What is Avidity Biosciences Inc (RNA)'s business?

Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.

What is the price predicton of RNA Stock?

What is Avidity Biosciences Inc (RNA)'s revenue for the last quarter?

Avidity Biosciences Inc revenue for the last quarter amounts to 12.48M USD, increased 434.03 % YoY.

What is Avidity Biosciences Inc (RNA)'s earnings per share (EPS) for the last quarter?

Avidity Biosciences Inc. EPS for the last quarter amounts to -1.27 USD, increased 95.38 % YoY.

What changes have occurred in the market's expectations for Avidity Biosciences Inc (RNA)'s fundamentals?

How many employees does Avidity Biosciences Inc (RNA). have?

Avidity Biosciences Inc (RNA) has 391 emplpoyees as of January 09 2026.

What is Avidity Biosciences Inc (RNA) market cap?

Today RNA has the market capitalization of 10.91B USD.